Abstract
Twenty-eight male Sprague Dawley rats were divided into two groups: a control group (C) of 15 animals and a streptozotocin-induced diabetes group mildly balanced by insulin (D) of 13 animals. After 15 weeks, plasma and high-density lipoprotein (HDL) lipids were determined in each group. Apoprotein A-I concentration was evaluated in HDL fractions. The capacity of the HDL fraction to inhibit thrombin and ADP-induced aggregation of normal platelets was determined for each rat, and in an additional experiment the relation dose-effect of HDL was established. The effect of HDL of the two groups on the stabilization of prostacyclin was compared by aggregation bioassay. After 15 weeks, HDL cholesterol (free+esterified) tended to increase in group D compared with group C (P<0.08). By contrast, apoprotein A-I was very significantly decreased in HDL-D compared with HDL-C (P<0.001). These alterations were accompanied by a significantly decreased capacity of HDL (60 μg/ml platelet suspension) to inhibit ADP-induced aggregation (P<0.0001) in group D compared with group C. Furthermore, HDL-D incubated 45 or 90 min with prostacyclin showed a significantly decreased capacity to stabilize prostacyclin compared with HDL-C (P<0.04;P<0.03, respectively). These alterations in HDL could be involved in thrombosis and atheromatous complications associated with this disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Tall AR, Plasma high density lipoproteins; metabolism and relationship to atherogenesis. J Clin Invest 86:379–384, 1990
Aviram M, Brook JG, Platelet interaction with high and low density poproteins. Atherosclerosis 46:259–268, 1983
Curtiss LK, Plow EF, Interactions of plasma lipoproteins with human platelets. Blood 64:365–374, 1984
Hassall DGL, Forrest RA, Bruckdorfer KR, Marenah CB, Turner C, Cortese N, Miller E, Lewis B, Influence of plasma lipoproteins on platelet aggregation in a normal male population. Arteriosclerosis 3:332–338, 1983
Yui Y, Aoyama T, Morishita H, Takahashi M, Takatsu Y, Kawai C, Serum prostacyclin stabilizing factor is identical to apolipoprotein A-I. J Clin Invest 82:803–807, 1988
Watanabe J, Wolthmann HJ, Klein RL, Colwell JA, Lopes-Virella MF, Enhancement of platelet aggregation by low density lipoproteins from IDDM patients. Diabetes 37:1652–1657, 1988
Valentovic MA, Lubway WC, Impact of insulin or tolbutamide treatment on 14C arachidonic acid conversion to prostacyclin and/or thromboxane in lungs, aortas, and platelets of streptozotocin-induced diabetic rats. Diabetes 32:846–851, 1983
Bar-on H, Roheim P, Eder H, Serum lipoproteins and apolipoproteins in rats with streptozotocin-induced diabetes. J Clin Invest 57:714–721, 1976
Colette C, Pares-Herbute N, Monnier LH, Cartry E, Platelet function in type I diabetes: effects of supplementation with large dose of vitamin E. Am J Clin Nutr 47:256–261, 1988
Burnstein M, Scholnick H, Morfin R, Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res 11:583–595, 1970
Talussot C, Ponsin G, Cholesterol-induced alteration of apolipoprotein AI conformation in reassembled high density lipoproteins. Biochimie 73:1173–1178, 1991
Leclerq M, Bourgeay-Causse M, Une methode simple, fiable et rapide: dosage simultané du rétinol et du tocopherol sériques par chromatographie liquide haute performance. Rev Inst Pasteur 14:475–496, 1981
Folch JM, Lees M, Sloane SGM, A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226:497–507, 1957
Omodeo Sale F, Maechesini S, Fishman P, Berra B, A sensitive enzymatic assay for determination of cholesterol in lipid extracts. Anal Biochem 142:347–350, 1984
France D, Hughes T, Miserendino R, Spirito S, Babiak J, Eskesen B, Tapparelli C, Paterniti J, Nonimmunochemical quantitation of mammalian apolipoprotein A-I in whole serum or plasma by non reducing gel electrophoresis. J Lipid Res 30: 1997–2004, 1989
Aoyama T, Yui Y, Morishita H, Kawai C, Prostaglandin I2 half life regulated by high density lipoproteins is decreased in acute myocardial infarction and unstable angina pectoris. Circulation 81:1784–1791, 1990
Parthasarathy S, Barnett J, Fong LG, High density lipoprotein inhibits the oxidative modification of low density lipoprotein. Biochim Biophys Acta 1044:275–283, 1990
Colwell J, Lopes-Virella M, A review of the development of large vessel disease in diabetes mellitus. N Engl J Med 85 (Suppl 5A):113–118, 1988
Nikkila EA, Hermila P, Serum lipids and lipoproteins in insulin treated diabetes. Demonstration of increased high density lipoprotein concentrations. Diabetes 27:1078–1086, 1978
Sagel J, Colwell JA, Crook L, Liamins M, Increased platelet aggregation in early diabetes mellitus. Ann Intern Med 82: 733–738, 1975
Weisgraber KH, Mahley RW, Characterization of rat plasma lipoproteins. In: Lewis L, Naito H (eds) Handbook of electrophoresis. CRC Press, Boca Raton, Florida, pp 103–132, 1983
Davenas E, Ciavatti M, Nordoy A, Renaud S, Effects of dietary lipids on behaviour, lipid biosynthesis and lipid composition in rat platelets. Biochim Biophys Acta 793:278–286, 1984
Desai K, Bruckdorfer R, Hutton RA, Owen JS, Binding of apo-E rich high density lipoprotein particles by saturables sites on human blood platelets inhibits agonist-induced platelet aggregation. J Lipid Res 30:831–840, 1989
Shattil SJ, Anaya-Galindo R, Bennett J, Colman RW, Cooper RA, Platelet hypersensitivity induced by cholesterol incorporation. J Clin Invest 53:636–643, 1975
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ginon, I., Talussot, C., Ponsin, G. et al. Decreased capacity to inhibit platelet hyperactivity and to stabilize prostacyclin of high-density lipoproteins in experimental diabetes. Acta Diabetol 32, 170–175 (1995). https://doi.org/10.1007/BF00838487
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00838487